WHO considers multiple sclerosis treatments essential
- PMID: 38267183
- DOI: 10.1016/S1474-4422(23)00505-7
WHO considers multiple sclerosis treatments essential
Conflict of interest statement
We declare no competing interests. No funding was provided for the writing or the decision to submit this Correspondence. MSIF funded part of the research work, and co-ordinated the guidelines and preparation of the application to WHO's EML to which this Correspondence refers. MSIF is an alliance of national multiple sclerosis organisations. MSIF receives income from a wide range of sources, including health-care and other companies, individuals, member organisations, campaigns, foundations, and trusts. During the past 5 years, MSIF received funding from the following companies: Bristol Myers Squibb, Sanofi, Merck, Viatris (formerly Mylan), Novartis, Biogen, and Roche—all of which is publicly disclosed. MSIF's independence and all the donations from the health-care industry are governed by MSIF's health-care policy. MSIF has not received any funding from industry for its access to medicines work in 2019–23.
Comment on
-
Towards equitable access to treatment for multiple sclerosis.Lancet Neurol. 2023 Mar;22(3):189. doi: 10.1016/S1474-4422(23)00041-8. Lancet Neurol. 2023. PMID: 36804076 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical